Baijin Life Science Holdings Limited submitted its monthly return for the period ended 31 March 2026, confirming that neither authorised nor issued share capital changed during the month.

Authorised Share Capital • Remained at 10.00 billion ordinary shares with a par value of HK$0.02, equivalent to HK$200.00 million.

Issued Share Capital • Outstanding ordinary shares stayed at 932.25 million. • No treasury shares were held or cancelled, leaving total issued shares unchanged at 932.25 million.

Public Float Compliance • The company affirmed compliance with the Main Board’s minimum public float requirement of 25 percent of issued shares.

Corporate Actions • No share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or cancelled during the month.

Regulatory Filing • The return was filed on 1 April 2026 and signed by Director Cheung Sze Ming.